|Year : 2018 | Volume
| Issue : 4 | Page : 971-975
Role of hypertonic sodium lactate in traumatic brain injury management
Muhammad Reza Arifianto MD 1, Achmad Zuhro Ma'ruf1, Arie Ibrahim2, Abdul Hafid Bajamal3
1 Department of Neurosurgery, Kanudjoso Djatiwibowo Hospital, Balikpapan, Indonesia
2 Department of Neurosurgery, AW Syahranie Hospital / Faculty of Medicine – Mulawarman University, Samarinda, Indonesia
3 Department of Neurosurgery, Dr. Soetomo General Hospital / Faculty of Medicine – Airlangga University, Surabaya, Indonesia
|Date of Web Publication||23-Oct-2018|
Dr. Muhammad Reza Arifianto
Galaxy Bumi Permai L1/12B, Surabaya
Source of Support: None, Conflict of Interest: None
Traumatic brain injury (TBI) following increased intracranial pressure (ICP) is a neuroemergency case which should be managed promptly to prevent secondary brain injury. This will lead to a condition called cerebral energy dysfunction which is an important determinant factor toward worse outcome. Lactate, which was historically known as an end waste product, now is considered as an alternative cerebral energetic fuel. Hypertonic sodium lactate (HSL) is a promising hyperosmolar fluid which serves not only to decrease ICP but also to readily supply exogenous lactate to fulfill increased cerebral energy demand. Pioneer studies have shown the harmlessness and usefulness of HSL in treating pathological condition including TBI.
Keywords: Hypertonic sodium lactate, intracranial pressure, traumatic brain injury
|How to cite this article:|
Arifianto MR, Ma'ruf AZ, Ibrahim A, Bajamal AH. Role of hypertonic sodium lactate in traumatic brain injury management. Asian J Neurosurg 2018;13:971-5
|How to cite this URL:|
Arifianto MR, Ma'ruf AZ, Ibrahim A, Bajamal AH. Role of hypertonic sodium lactate in traumatic brain injury management. Asian J Neurosurg [serial online] 2018 [cited 2020 Jun 3];13:971-5. Available from: http://www.asianjns.org/text.asp?2018/13/4/971/230991
| Introduction|| |
Cerebral energy dysfunction in traumatic brain injury (TBI) is one of the most important determinant factors that should be recognized in the early management of TBI. This condition becomes one of the strong predictors toward worse clinical and neurological outcome if it is not managed promptly. In the early phase of TBI, brain develops hypermetabolism to adapt from injury which affects glucose usage in the blood. Glucose requirement increases, and if it is not equaled by the glucose adequate supply, it will result in brain starvation and cerebral energy dysfunction which lead to the worse prognosis., The main objective treatment of TBI patients is to prevent or minimize the secondary brain injury by maintaining adequate blood flow to increase oxygen and glucose supply. In the past, glucose is considered as the one and only substance which can be metabolized by the brain to gain energy; however, the latest researches showed that lactate can be utilized as emergency or primary addition for cerebral energetic substrates.,, It was first introduced by Pellerin and Magistretti in 1994 as astrocyte-neuron lactate shuttle hypothesis (ANLS). Hypertonic sodium lactate (HSL) is the only fluid which not only has the effects as a lactate supplementation but also functions as the hyperosmolar therapy for the TBI patients with increased intracranial pressure (ICP). In this article, we will discuss the effectiveness of HSL as the lactate supplementation without ignoring the main effect as the hyperosmolar therapy based on the latest clinical evidence.
| Cerebral Metabolism: What Have We Learned?|| |
Pertinent studies from the last decades have changed the concept of cerebral metabolism in normal and abnormal conditions of brain. Basically, in normal conditions, human brain mainly utilized glucose as the main energy source for maintaining normal functions. The energy was generated from aerobic metabolisms which require adequate oxygen supply, through the glycolysis process and tricarboxylic acid cycle (TCA) of the pyruvate. This process is highly effective energy production, which can generate 36 adenosine triphosphate (ATP) molecules per molecules of glucose. Besides its main function as energy fuel, glucose also acts as neurotransmitter and the regulator of cell redox state through pentose phosphate pathway. The illustration of normal cerebral metabolic pathway is described in [Figure 1]a.
|Figure 1: Cerebral metabolism in (a) normal conditions and (b) following traumatic brain injury.1, 9, 10. NT – neurotransmitters; PPP – pentose phosphate pathway; ATP – Adenosine Triphosphate|
Click here to view
Following TBI, human body will be put in a great stress which results in hypermetabolism state as compensatory method. More energies are required to maintain the normal function of brain such as maintaining Na+/K+ATPase pump activity. When the energy requirement of the brain is not balanced by the glucose supply, brain will utilize lactate as an emergency energy substrate. This theory is proved by experimental studies using cerebral microdialysis (CMD) in brain glucose-deprived state, and studies using jugular bulb venous catheter which have shown increase of cerebral lactate uptake by the brain in TBI setting. In TBI, there can be disruption in cerebral blood flow which results in brain ischemic or hypoxic condition. In this setting, oxygen supply is not adequate to perform aerobic metabolism; therefore, brain will undergo anaerobic metabolism which is used as compensatory method. Anaerobic metabolisms will produce lactate from cytosolic pyruvate through continuous anaerobic ATP synthesis to generate only 2 ATP molecules. Sustained hypoxic state and anaerobic metabolism will lead to lactate overproduction which shown by increased, elevated lactate-to-pyruvate ratio. This condition will lead to metabolic crisis in which only increase of oxygen supply is the only way to solve the crisis.
| Role of Lactate in Traumatic Brain Injury|| |
Lactate is a waste product of anaerobic metabolism. This old statement is no longer used. It was Pellerin and Magistretti who introduced ANLS hypothesis. In their study, they described that lactate that was formed within the brain parenchyma through glutamate-activated glycolysis in astrocytes could fulfill energetic needs of neurons during activation. Since this study have changed the role of lactate in brain energetic fuel, several studies regarding lactate usage are considerably emerged. Animal and human studies showed that elevation of lactate (within a physiological range) can prevent the detrimental neurological effect of hypoglycemia, also substantially diminished catecholamines, growth hormone, cortisol, and symptomatic responses to hypoglycemia. Experimental data on rat hippocampi with ischemia-reperfusion injury found that lactate can support neuronal survival in conjunction with glucose. Furthermore, several in vivo experimental data support that lactate can decrease lesion volume, reduction of cognitive deficit, increase cerebral blood flow (CBF), and improve EEG function in rats induced by neuronal insult.,,,,,, In 2009, Gallagher et al. demonstrated the first direct human experimental in 14 severe TBI patients using labeled isotopic lactate perfusion through infusion via microdialysis catheters. The result showed that the injured brain utilizes endogenous lactate through the TCA cycle. Furthermore, in 2015, Glenn et al. reconfirmed in their study that lactate production during TBI was increased and was also consumed by injured human brain. They also concluded that exogenous lactate supplementation could help supply neuroenergetic fuel demand during TBI. This study confirmed the ANLS and supported the concept that lactate could be used as energy substrate. Brain parenchyma might use astrocytic glycolysis to produce lactate as fuel in consequence of the increase of energy needs in TBI. In addition, glutamate, in the setting of nonhypoxic TBI, also stimulates glycogen stored in astrocyte to be metabolized into lactate. This condition is precipitated by the increase of cerebral energy need and only lasting for a short period. The illustration of lactate's role in neuroenergetics during TBI is shown in [Figure 1]b.
As the supporting study, Bouzat et al. in 2014 conducted prospective study in 15 patients with severe TBI which were monitored with CMD, brain tissue oxygen tension PO2(PbtO2), and ICP. Each patient was given with a 3 h intravenous infusion of HSL (aiming to increase systemic lactate to consentration of 5 mmol/L), administered in the early phase following TBI. They concluded that injured human brain can utilize exogenous supplemental lactate aerobically as a preferential energy substrate. HSL therapy also had beneficial cerebral metabolic and hemodynamic effects after TBI by increasing the availability of cerebral extracellular pyruvate and glucose, coupled with a reduction of brain glutamate and ICP. Quintard et al. in their study showed that HSL infusion during TBI significantly increased concentrations of CMD glucose, CMD lactate, and arterial blood lactate. It means that HSL infusion during TBI adds more energy supplies in consequence to increased energy demand by the brain. This study has convinced us that HSL has many benefits in the setting of TBI management.
| The Usage of Hypertonic Sodium Lactate in Traumatic Brain Injury Management|| |
Increased ICP in the TBI patients is a major emergency in the neurosurgery field. If the increased ICP is caused by the space occupying lesions as in the intracranial bleeding, rapid reduction of ICP is indispensable., Decompressive craniectomy becomes the primary choice to control increased ICP if it meets the indication criteria.,, However, the operative therapy frequently cannot be done due to the condition of TBI patient who does not meet the criteria. At this point, conservative therapy will consider as the primary therapy to reduce increased ICP. The Brain Trauma Foundation has recommended that ICP-reducing therapy should begin at >20 mmHg pressures. One of the main conservative therapies to reduce ICP for TBI patients is hyperosmolar therapy. Currently, only 2 agents are used for this purpose: mannitol and hypertonic saline (HTS). Both the fluids have no superiority among them, even though latest studies showed that HTS had more benefits than mannitol in reducing ICP., There is another hyperosmolar fluid which can be used as an alternative to reduce ICP, which is HSL fluid. The reduction of ICP mechanism using HSL is similar with HTS; HSL lowers ICP by increasing intravascular osmotic pressure that will drain extracellular fluid into intravascular compartment. Initially, HSL lowers blood viscosity through increased plasma volume, which results in an increased microvascular flow and tissue oxygenation. Increased tissue perfusion leads to the vasoconstriction reflex that limits blood supply to the brain tissue and, hence, decreases ICP. Meanwhile, because of its hypertonicity, HSL causes increasing of intravascular osmotic pressure and widening of the osmotic gradient between intravascular and extravascular compartments. Eventually, the edematous fluid will be drawn into the blood vessel and greatly contribute to lowering ICP.,
HSL 0.5 M is a fluid which can be similarly considered with the HTS 3% because of the same osmolarity (1027 mOsmol/kg vs. 1020.42 mOsmol/kg, respectively). Even though it has the same osmolarity, both of the fluids have different ion composition. HSL contains inorganic cation (Na+, K+, and Ca2+) and organic anion of lactate, while HTS 3% has inorganic cation and anion of sodium and chloride. Several researches have been proven that HSL significantly reduces ICP and maintain mean arterial pressure (MAP) remained in the figures recommended by the Brain Trauma Foundation. In addition, HSL also has the additional effect in the improvement of cognitive function after TBI. Compared with the other hyperosmolar fluids, it may be caused by the lactate inside the fluid which has effect as fuel additional energy when the brain undergoes anaerobic metabolism and hypermetabolism.
| Efficacy Comparison of Hypertonic Sodium Lactate and Other Hyperosmolar Fluids in Traumatic Brain Injury Management|| |
Several pioneer studies have shown the harmlessness and usefulness of HSL in treating pathological condition aside of TBI. For example, HSL has been shown (i) to restore hemodynamic status in dengue shock syndrome with minimal fluid accumulation, (ii) to decrease fluid accumulation during burn shock resuscitation, and (iii) to improve cardiac performance in patients undergoing elective cardiac surgery and during acute heart failure. Several studies have been emerged in TBI management using HSL. Starting as the first study, in 2009, Ichai et al. conducted a prospective, open randomized study to compare sodium lactate and mannitol in the treatment of episode intracranial hypertension in severe TBI patients. Thirty-four patients with isolated severe TBI (Glasgow coma scale < or=8) and intracranial hypertension were divided into two groups, both received equally hyperosmolar and isovolume therapy, consisting of either mannitol or sodium lactate (1100 mosm/L for LAC and 1160 mosm/L for MAN). Efficacy in lowering ICP after 4 h was the primary endpoint and the percentage of successfully treated episodes of intracranial hypertension as the secondary endpoint. The result showed that the effect of the lactate solution on ICP was significantly more pronounced (7 vs. 4 mmHg, P = 0.016), more prolonged (4th-h-ICP decrease: −5.9 ± 1 vs. −3.2 ± 0.9 mmHg, P = 0.009), and more frequently successful (90.4 vs. 70.4%, P = 0.053) compared to mannitol.
As the second study, in 2013, Ichai et al. conducted a double-blind, randomized, controlled trial including 60 patients with severe TBI requiring ICP monitoring. Patients were randomly assigned in a 1:1 ratio to receive a 48-h continuous infusion at 0.5 ml/kg/h of either SL (SL group) or isotonic saline solution (control group) within the first 12 h posttrauma. The primary outcome was the number of increased ICP (≥20 mmHg) requiring a specific treatment. The results showed that SL group decreased the occurrence of increased ICP episodes as compared to control group within 48-h study period (23 vs. 53 episodes, respectively [P < 0.05]). These findings suggest that SL solution could be considered as an alternative treatment to prevent increased ICP following severe TBI.
In Indonesia, Bisri et al. in 2016 conducted a prospective, single-blind, randomized, controlled study in 60 mild TBI patients who undergo neurosurgery procedure. Patients were randomly grouped into HSL group or hyperosmolar sodium chloride (HSS) group; each group received either intravenous infusion of HSL or NaCl 3% at 1.5 ml/KgBW within 15 min before neurosurgery procedure. The primary goal was cognitive function, as assessed by mini-mental state examination (MMSE) score at 24 h and 30 and 90 days postsurgery and analyzed by the ANOVA with repeated measures test. The results suggested that HSL group had better improvement in MMSE score than HSS group. The authors concluded that HSL infusion during mild TBI improved cognitive function better than 3% sodium chloride. Furthermore, in 2014, Ahmad and Hannaconducted a randomized, controlled study in 42 moderate TBI patients undergoing craniectomy. The patients were divided into Group M (n = 21) received 2.5 mL/kg 20% mannitol and group HSL received 2.5 mL/kg 0.5M HSL. MAP, central venous pressures (CVP), and urine output were measured after induction and at 15, 30, 45, and 60 min after infusion. The results showed that MAP at 60 min was significantly higher in HSL group than M group (81.66 ± 7.85 vs. 74.33 ± 6.18 mmHg; P = 0.002). There was no difference in brain relaxation (P = 0.988). A significant increase in blood glucose level was observed in group HSL (17.95 ± 11.46 mg/dL; P = 0.001). The authors concluded that half-molar HSL was as effective as 20% mannitol in producing brain relaxation, with better hemodynamic stability and gave significant increase in blood glucose level. Studies regarding the efficacy of HSL in TBI management are summarized in [Table 1].
|Table 1: List of studies regarding efficacy of hypertonic sodium lactate in Traumatic Brain Injury management|
Click here to view
| Conclusion|| |
Lactate which is historically considered as an end waste product for the last decade emerges as an important fuel and plays an important role in neuroenergetic metabolism. It is clear that now lactate serves as preferential substitute fuel besides glucose in the setting of TBI. In TBI, HSL not only works for reducing ICP but also serves as an exogenous supplementation for increasing supply of neuroenergetic fuel which has quality as neuroprotective fluid. Therefore, HSL may serve as an alternative fluid of choice in managing intracranial hypertension in TBI patients. However, further evidences are warranted to confirm this finding.
Financial support and sponsorship
Conflict of interest
There are no conflicts of interest.
| References|| |
Patet C, Suys T, Carteron L, Oddo M. Cerebral lactate metabolism after traumatic brain injury. Curr Neurol Neurosci Rep 2016;16:31.
Foley N, Marshall S, Pikul J, Salter K, Teasell R. Hypermetabolism following moderate to severe traumatic acute brain injury: a systematic review. J Neurotrauma 2008;25:1415-31.
Rostami E, Engquist H, Enblad P. Imaging of cerebral blood flow in patients with severe traumatic brain injury in the neurointensive care. Front Neurol 2014;5:114.
Vespa PM, McArthur D, O'Phelan K, Glenn T, Etchepare M, Kelly D, et al.
Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: a microdialysis study. J Cereb Blood Flow Metab 2003;23:865-77.
Glenn TC, Kelly DF, Boscardin WJ, McArthur DL, Vespa P, Oertel M, et al.
Energy dysfunction as a predictor of outcome after moderate or severe head injury: indices of oxygen, glucose, and lactate metabolism. J Cereb Blood Flow Metab 2003;23:1239-50.
Jalloh I, Helmy A, Shannon RJ, Gallagher CN, Menon DK, Carpenter KL, et al.
Lactate uptake by the injured human brain: evidence from an arteriovenous gradient and cerebral microdialysis study. J Neurotrauma 2013;30:2031-7.
Fontaine E, Orban JC, Ichai C. Hyperosmolar sodium-lactate in the ICU: vascular filling and cellular feeding. Crit Care 2014;18:599.
Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994;91:10625-9.
Carpenter KL, Jalloh I, Hutchinson PJ. Glycolysis and the significance of lactate in traumatic brain injury. Front Neurosci 2015;9:112.
Bouzat P, Oddo M. Lactate and the injured brain: friend or foe? Curr Opin Crit Care 2014;20:133-40.
Chen T, Qian YZ, Di X, Zhu JP, Bullock R. Evidence for lactate uptake after rat fluid percussion brain injury. Acta Neurochir Suppl 2000;76:359-64.
Dienel GA. Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab 2012;32:1107-38.
Rogatzki MJ, Ferguson BS, Goodwin ML, Gladden LB. Lactate is always the end product of glycolysis. Front Neurosci 2015;9:22.
Maran A, Cranston I, Lomas J, Macdonald I, Amiel SA. Protection by lactate of cerebral function during hypoglycaemia. Lancet 1994;343:16-20.
Cater HL, Chandratheva A, Benham CD, Morrison B 3rd
, Sundstrom LE. Lactate and glucose as energy substrates during, and after, oxygen deprivation in rat hippocampal acute and cultured slices. J Neurochem 2003;87:1381-90.
Alessandri B, Schwandt E, Kamada Y, Nagata M, Heimann A, Kempski O. The neuroprotective effect of lactate is not due to improved glutamate uptake after controlled cortical impact in rats. J Neurotrauma 2012;29:2181-91.
Berthet C, Castillo X, Magistretti PJ, Hirt L. New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration. Cerebrovasc Dis 2012;34:329-35.
Berthet C, Lei H, Thevenet J, Gruetter R, Magistretti PJ, Hirt L. Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab 2009;29:1780-9.
Herzog RI, Jiang L, Herman P, Zhao C, Sanganahalli BG, Mason GF, et al.
Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. J Clin Invest 2013;123:1988-98.
Holloway R, Zhou Z, Harvey HB, Levasseur JE, Rice AC, Sun D, et al.
Effect of lactate therapy upon cognitive deficits after traumatic brain injury in the rat. Acta Neurochir (Wien) 2007;149:919-27.
Rice AC, Zsoldos R, Chen T, Wilson MS, Alessandri B, Hamm RJ, et al.
Lactate administration attenuates cognitive deficits following traumatic brain injury. Brain Res 2002;928:156-9.
Ros J, Pecinska N, Alessandri B, Landolt H, Fillenz M. Lactate reduces glutamate-induced neurotoxicity in rat cortex. J Neurosci Res 2001;66:790-4.
Gallagher CN, Carpenter KL, Grice P, Howe DJ, Mason A, Timofeev I, et al.
The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain 2009;132(Pt 10):2839-49.
Glenn TC, Martin NA, Horning MA, McArthur DL, Hovda DA, Vespa P, et al.
Lactate: brain fuel in human traumatic brain injury: a comparison with normal healthy control subjects. J Neurotrauma 2015;32:820-32.
Steinman MQ, Gao V, Alberini CM. The role of lactate-mediated metabolic coupling between astrocytes and neurons in long-term memory formation. Front Integr Neurosci 2016;10:10.
Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, et al.
Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med 2014;40:412-21.
Quintard H, Patet C, Zerlauth JB, Suys T, Bouzat P, Pellerin L, et al.
Improvement of neuroenergetics by hypertonic lactate therapy in patients with traumatic brain injury is dependent on baseline cerebral lactate/pyruvate ratio. J Neurotrauma 2016;33:681-7.
Hawthorne C, Piper I. Monitoring of intracranial pressure in patients with traumatic brain injury. Front Neurol 2014;5:121.
Seppelt I. Intracranial hypertension after traumatic brain injury. Indian J Crit Care Med 2004;8:120. [Full text]
Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, et al.
Surgical management of traumatic parenchymal lesions. Neurosurgery 2006;58 3 Suppl: S25-46.
Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, et al.
Surgical management of acute epidural hematomas. Neurosurgery 2006;58 3 Suppl: S7-15.
Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, et al.
Surgical management of acute subdural hematomas. Neurosurgery 2006;58 3 Suppl: S16-24.
Ropper AH. Hyperosmolar therapy for raised intracranial pressure. N Engl J Med 2012;367:746-52.
Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al.
Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017;80:6-15.
Arifianto M, Ma'ruf A, Ibrahim A. Efficacy comparison of mannitol and hypertonic saline for traumatic brain injury (TBI) treatment. Bali Med J 2016;5:170-6.
Boone MD, Oren-Grinberg A, Robinson TM, Chen CC, Kasper EM. Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned? Surg Neurol Int 2015;6:177.
Bisri T, Utomo BA, Fuadi I. Exogenous lactate infusion improved neurocognitive function of patients with mild traumatic brain injury. Asian J Neurosurg 2016;11:151-9.
] [Full text]
Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, et al.
Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med 2009;35:471-9.
Mustafa I, Leverve XM. Metabolic and hemodynamic effects of hypertonic solutions: sodium-lactate versus sodium chloride infusion in postoperative patients. Shock 2002;18:306-10.
Somasetia DH, Setiati TE, Sjahrodji AM, Idjradinata PS, Setiabudi D, Roth H, et al.
Early resuscitation of dengue shock syndrome in children with hyperosmolar sodium-lactate: a randomized single-blind clinical trial of efficacy and safety. Crit Care 2014;18:466.
Belba MK, Petrela EY, Belba GP. Comparison of hypertonic vs. isotonic fluids during resuscitation of severely burned patients. Am J Emerg Med 2009;27:1091-6.
Nalos M, Leverve X, Huang S, Weisbrodt L, Parkin R, Seppelt I, et al.
Half-molar sodium lactate infusion improves cardiac performance in acute heart failure: a pilot randomised controlled clinical trial. Crit Care 2014;18:R48.
Ichai C, Payen JF, Orban JC, Quintard H, Roth H, Legrand R, et al.
Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial. Intensive Care Med 2013;39:1413-22.
Ahmad MR, Hanna H. Effect of equiosmolar solutions of hypertonic sodium lactate versus mannitol in craniectomy patients with moderate traumatic brain injury. Med J Indones 2014;23:30.